Home › Preeclampsia › NCT06168461

Daily Aspirin Treatment After Preeclampsia

Aspirin for the Treatment of Vascular Dysfunction After Preeclampsia

Who can join

Ages 18 to 50 · Women

Inclusion Criteria:

* had preeclampsia in the past 5 years,
* 18 years or older

Exclusion criteria:

* current daily aspirin use,
* skin diseases,
* current tobacco or nicotine use (including vaping),
* diagnosed or suspected hepatic or metabolic disease including chronic kidney disease (CKD) defined as reduced eGFR \< 60 mL/min/1.73m2,
* statin or other cholesterol-lowering medication,
* current antihypertensive medication,
* history of hypertension prior to pregnancy,
* history of gestational diabetes,
* currently pregnancy,
* body mass index \<18.5 kg/m2,
* allergy to materials used during the experiment.(e.g. latex),
* known allergies to study drugs,
* bleeding disorders, peptic ulcer disease, gastritis, GI bleeding and gastroesophageal reflux disease (GERD).

About the study

Women who develop preeclampsia during pregnancy are four times more likely to develop cardiovascular disease later in life, even if they are otherwise healthy. The reason why this occurs may be related to lasting blood vessel damage after the pregnancy but there are currently no specific treatment strategies to prevent this disease progression. This study addresses this public health issue by examining whether starting low dose aspirin therapy after pregnancy is an effective treatment for lasting blood vessel damage in order to inform better clinical management of cardiovascular disease risk in women who have had preeclampsia.

What is being tested

• Aspirin (drug)
• Placebo (drug)

Sponsor: Anna Stanhewicz, PhD · Participants: 40 · Started: Nov 1, 2023

Contact the study team

• Anna Reid-Stanhewicz, PHD · Phone: 319-467-1732

Official record on ClinicalTrials.gov — NCT06168461

Locations in the U.S.

Conditions

• Preeclampsia

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.